Extension of AVXL's adult Rett Syndrome study shows continued improvement and disease-modifying effects. The study was a double-blind originally, but they put ALL the participants on the drug for the open-label extension study. Statistically significant improvements for them. And remember, this is in ADULT Rett Syndrome patients. It's harder to treat in adults. Let's hopes they can get this kind of result in kids -- because this halts the disease progression in adults, maybe it can keep kids from becoming so disabled.

http://newsfile.refinitiv.com/getnewsfile/v1/...theme=true